High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses

Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M, Salvado A, McDougall K, Albitar M, Radich J, Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) Trial Study Group; Leonard Kalman

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses

Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M, Salvado A, McDougall K, Albitar M, Radich J, Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) Trial Study Group
, Leonard Kalman

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	27
State	Published - 2009

Disciplines

Medicine and Health Sciences

Cite this

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. / Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) Trial Study Group, Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M, Salvado A, McDougall K, Albitar M, Radich J,; Kalman, Leonard.
In: Journal of Clinical Oncology, Vol. 27, 2009.

Research output: Contribution to journal › Article › peer-review

Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) Trial Study Group, Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M, Salvado A, McDougall K, Albitar M, Radich J, ; Kalman, Leonard. / High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. In: Journal of Clinical Oncology. 2009 ; Vol. 27.

@article{e3dbd1d0c9ba4b51add1c56525e5eeec,

title = "High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses",

author = "\{Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) Trial Study Group\}, \{Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M, Salvado A, McDougall K, Albitar M, Radich J,\} and Leonard Kalman",

note = "J Clin Oncol. 2009 Oct 1;27(28):4754-9. doi: 10.1200/JCO.2008.20.3869. Epub 2009 Aug 31. Clinical Trial, Phase II; Multicenter Study; Research Support, Non-U.S. Gov't",

year = "2009",

language = "American English",

volume = "27",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses

AU - Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) Trial Study Group, Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M, Salvado A, McDougall K, Albitar M, Radich J,

AU - Kalman, Leonard

N1 - J Clin Oncol. 2009 Oct 1;27(28):4754-9. doi: 10.1200/JCO.2008.20.3869. Epub 2009 Aug 31. Clinical Trial, Phase II; Multicenter Study; Research Support, Non-U.S. Gov't

PY - 2009

Y1 - 2009

UR - https://www.ncbi.nlm.nih.gov/pubmed/19720924

M3 - Article

VL - 27

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses

Disciplines

Other files and links

Cite this